SCHEMBL31753979

SCHEMBL31753979

COCCOc1cc2cccnc2cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
EGFR P00533 3/20 0.35
KDM1A O60341 4/20 0.34
GAK O14976 1/20 0.33
PDE10A Q9Y233 1/20 0.33
ALDH1A1 P00352 3/20 0.33
TLR8 Q9NR97 2/20 0.33
ALOX15 P16050 1/20 0.33
HTT P42858 1/20 0.33
ALPL P05186 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TSHR P16473 1/20 0.32
P2RX3 P56373 1/20 0.32
P2RX2 Q9UBL9 1/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22324231 0.89 PDGFRB (0.47) PDGFRBPDGFRAEGFRPDE10AALDH1A1
SCHEMBL16431930 0.86 PDGFRB (0.59) PDGFRBPDGFRAEGFRPDE10AALDH1A1
SCHEMBL22323962 0.84 PDGFRB (0.47) PDGFRBPDGFRAEGFRPDE10AALDH1A1
SCHEMBL29447097 0.84 PDGFRB (0.47) PDGFRBPDGFRAEGFRPDE10AALDH1A1
SCHEMBL28694507 0.83 PDGFRB (0.41) PDGFRBPDGFRAEGFRPDE10AALOX15
SCHEMBL21645897 0.81 PDGFRB (0.59) PDGFRBPDGFRAEGFRPDE10AALDH1A1
SCHEMBL28102697 0.79 PDGFRB (0.67) PDGFRBPDGFRAEGFRKDM1AGAK
SCHEMBL262387 0.74 LPL (0.37) KDM1AALDH1A1HTTGAANPSR1
SCHEMBL29534512 0.74 LPL (0.37) KDM1AALDH1A1HTTGAANPSR1
SCHEMBL19491485 0.73 DGAT1 (0.33) EGFRKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 PDGFRB 3552/4885PDGFRA 4055/4885EGFR 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.